Acute myeloid leukemia with myelodysplasia-related changes
At a Glance
Acute myeloid leukemia with myelodysplasia-related changes is a fast-growing cancer of the blood and bone marrow characterized by specific genetic abnormalities, a history of blood disorders, or abnormal-looking blood cells under a microscope managed similarly to high-risk leukemia.
This condition predominantly affects older adults, with the median age of diagnosis being around 65 to 70 years, and it accounts for approximately 25% to 30% of all acute myeloid leukemia cases.
It is an acute and aggressive condition that requires immediate medical intervention, though it often arises from a chronic background of myelodysplastic syndrome.
The outlook is generally guarded with a lower likelihood of long-term survival compared to other leukemia subtypes, although newer targeted treatments and stem cell transplants can improve outcomes for eligible patients.
How It Affects You
- Bone Marrow Failure: This condition begins in the bone marrow, overcrowding it with abnormal cells and preventing the production of healthy red blood cells, white blood cells, and platelets.
- Systemic Symptoms: The lack of healthy blood cells leads to widespread effects such as severe fatigue, frequent infections due to a weakened immune system, and easy bruising or bleeding.
- Organ Involvement: As the leukemia cells circulate in the bloodstream, they can spread to other parts of the body, potentially affecting organs like the spleen, liver, and lymph nodes.
Causes and Risk Factors
Underlying Biological Mechanisms
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) develops when myeloid stem cells in the bone marrow acquire genetic mutations that prevent them from maturing into healthy blood cells. These cells, called blasts, multiply rapidly and crowd out normal cells. In this specific subtype, the leukemia cells share biological features with Myelodysplastic Syndromes (MDS), a group of disorders where blood cells do not form properly. This can happen because the leukemia evolved directly from a previously diagnosed MDS, or because the cells carry specific chromosomal damages (such as the loss of parts of chromosome 5 or 7) that are hallmark signs of MDS, even if the patient was never diagnosed with it before.
Risk Factors and Triggers
The primary risk factor is advancing age, as genetic errors in blood cells accumulate over time. A defined history of Myelodysplastic Syndrome (MDS) or Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN) is the strongest predictor. Certain genetic mutations, such as those in the ASXL1 or RUNX1 genes, are also closely linked to this condition. While it is distinct from "therapy-related AML," patients with a history of chemotherapy or radiation for other cancers may develop blood disorders that eventually progress to this form of leukemia.
Prevention Strategies
There is no known way to prevent the random genetic mutations that cause this condition. For patients already diagnosed with lower-risk Myelodysplastic Syndrome, monitoring and treating the underlying blood disorder may help manage the disease, but preventing progression to acute leukemia is difficult. Routine blood screenings are not recommended for the general population, but patients with known MDS are monitored closely to detect transformation early.
Diagnosis, Signs, and Symptoms
Clinically Meaningful Symptoms
Symptoms are largely caused by the failure of the bone marrow to produce healthy blood cells (pancytopenia). Early signs often include shortness of breath during normal activities, pale skin, and persistent fatigue due to anemia (low red blood cells). Patients may experience frequent or severe infections, such as pneumonia, because they lack functional white blood cells. A shortage of platelets often leads to easy bruising, tiny red spots on the skin (petechiae), frequent nosebleeds, or bleeding gums.
Diagnostic Tests and Tools
Diagnosis starts with a Complete Blood Count (CBC) to check for low numbers of healthy cells and the presence of leukemia cells in the blood. The definitive diagnosis requires a bone marrow aspiration and biopsy. Pathologists examine the sample for three specific criteria: a blast count of 20% or higher, signs of dysplasia (abnormal cell shape and size) in at least 50% of cells in two or more cell lines, and specific chromosomal or genetic abnormalities identified through cytogenetic testing and molecular profiling.
Differential Diagnosis
Clinicians must distinguish this condition from other subtypes of Acute Myeloid Leukemia (such as AML not otherwise specified), Myelodysplastic Syndromes (which have fewer than 20% blasts), and acute lymphoblastic leukemia. They also rule out non-cancerous causes of bone marrow failure, such as severe vitamin B12 deficiency or copper deficiency, which can mimic the abnormal cell appearance (dysplasia) seen in this leukemia.
Treatment and Management
Medications and Chemotherapy
Treatment typically involves induction chemotherapy to kill leukemia cells and restore normal blood production. A specific formulation of liposomal daunorubicin and cytarabine (often called CPX-351) has been developed and approved specifically for this high-risk subtype, showing better outcomes than standard chemotherapy mixtures. For patients who are older or cannot tolerate intensive chemotherapy, doctors may prescribe hypomethylating agents (such as azacitidine or decitabine) combined with a targeted drug called venetoclax, which helps promote cell death in cancer cells.
Stem Cell Transplantation
For patients who are fit enough and achieve remission, an allogeneic hematopoietic stem cell transplant (bone marrow transplant) is often the recommended consolidation therapy. This procedure replaces the diseased bone marrow with healthy cells from a donor and provides the best chance for a potential cure or long-term disease control.
Supportive Care and Monitoring
Supportive care is essential to manage symptoms. This includes blood and platelet transfusions to treat anemia and bleeding risks, as well as prophylactic antibiotics, antivirals, and antifungals to prevent infections. Regular blood tests and bone marrow exams are used to monitor response to treatment.
When to See a Doctor
Seek immediate medical care if you experience symptoms of severe infection, such as a fever over 100.4°F (38°C), chills, or confusion. Uncontrolled bleeding, sudden severe bruising, or extreme weakness also require emergency evaluation. Patients with a known history of MDS should report any sudden decline in energy or new symptoms to their hematologist immediately.
Severity and Prognosis
Severity and Disease Course
Acute myeloid leukemia with myelodysplasia-related changes is considered a high-risk subtype of leukemia. It is classified as "acute," meaning it progresses rapidly without treatment. The "myelodysplasia-related" features biologically make the cancer cells more resistant to standard chemotherapy compared to other forms of AML. Consequently, achieving a complete remission can be more difficult, and the risk of the disease returning (relapse) is higher.
Factors Influencing Outcomes
Prognosis is generally poor compared to other AML subtypes, but individual outcomes vary based on age, overall health, and the specific genetic mutations present. Patients who are able to undergo a stem cell transplant have significantly better long-term survival rates. The presence of complex chromosomal abnormalities (damage to multiple chromosomes) typically signals a more aggressive disease course.
Life Expectancy and Complications
Without treatment, life expectancy is measured in months. With modern therapies, survival can be extended significantly, though long-term cure rates remain lower than in low-risk AML. The most serious complications arise from the treatment itself or the disease, including life-threatening infections (sepsis) and severe bleeding events (hemorrhage) in the brain or gut.
Impact on Daily Life
Managing Daily Activities
Fatigue is a major challenge. Patients may need to conserve energy, prioritize essential tasks, and take frequent breaks. During treatment, the immune system is severely compromised, so avoiding crowds, wearing a mask, and practicing strict hand hygiene are necessary to avoid infections that could delay treatment.
Mental and Emotional Health
A diagnosis of acute leukemia is overwhelming. Anxiety regarding the prognosis and the intensity of treatment is common. Support groups for blood cancer patients can provide emotional relief. Palliative care specialists can also be involved early—not just for end-of-life care, but to help manage symptoms and stress throughout the treatment journey.
Questions to Ask Your Healthcare Provider
- Am I a candidate for the liposomal chemotherapy (CPX-351) specifically designed for this type of AML?
- What specific genetic mutations do I have, and how do they affect my risk level?
- Am I eligible for a stem cell transplant, and when should we start the donor search?
- If intensive chemotherapy is too strong for me, what are the success rates of lower-intensity options like venetoclax?
- What signs of infection should prompt me to go to the emergency room immediately?
Common Questions and Answers
Q: Is this condition the same as Myelodysplastic Syndrome (MDS)?
A: No. While they are related, this condition is an acute leukemia, meaning there are more than 20% immature blast cells in the marrow. MDS is considered a chronic precursor condition with fewer blast cells, although high-risk MDS can transform into this type of leukemia.
Q: Is this type of leukemia hereditary?
A: In the vast majority of cases, it is not hereditary. The genetic mutations that cause it are usually acquired during a person's lifetime (somatic mutations) and are not passed down to children. Rare familial syndromes exist but are uncommon.
Q: Can it be cured?
A: It is difficult to cure, but it is possible. An allogeneic stem cell transplant offers the only potential for a permanent cure. For patients who cannot have a transplant, treatment focuses on controlling the disease and extending life.
Q: Why is the prognosis often described as poor?
A: The cells in this subtype often have complex genetic defenses that help them survive standard chemotherapy. Because it affects older adults more frequently, patients may also have other health issues that limit the use of the strongest available treatments.